T-DM1 as a Treatment for Breast Cancer
Edith A. Perez, MD, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.
Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.
Clinical Pearls:
- T-DM1 is a combination of trastuzumab and a chemotherapy agent all in one compound
- Once the drug is injected into the vein, T-DM1 finds the cells that overexpress HER2 and then places the chemotherapy inside the tumor cell
- The results of the MARIANNE trial, which will examine T-DM1 plus pertuzumab, T-DM1 with pertuzumab or placebo, and trastuzumab plus a taxane (docetaxel or paclitaxel) in patients with metastatic breast cancer, could be practice changing
Recent Videos
Related Content
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
June 17th 2025Article
In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.
Read More
